Decreased severity of collagen antibody and lipopolysaccharide-induced arthritis in human IL-32β overexpressed transgenic mice

Interleukin (IL)-32, mainly produced by T-lymphocytes, natural killer cells, epithelial cells, and blood monocytes, is dominantly known as a pro-inflammatory cytokine. However, the role of IL-32 on inflammatory disease has been doubtful according to diverse conflicting results. This study was designed to examine the role of IL-32β on the development of collagen antibody (CAIA) and lipopolysaccharide (LPS)-induced inflammatory arthritis. Our data showed that the paw swelling volume and clinical score were significantly reduced in the CAIA and LPS-treated IL-32β transgenic mice compared with non-transgenic mice. The populations of cytotoxic T, NK and dendritic cells was inhibited and NF-κB and STAT3 activities were significantly lowered in the CAIA and LPS-treated IL-32β transgenic mice. The expression of pro-inflammatory proteins was prevented in the paw tissues of CAIA and LPS-treated IL-32β transgenic mice. In addition, IL-32β altered several cytokine levels in the blood, spleen and paw joint. Our data indicates that IL-32β comprehensively inhibits the inflammation responses in the CAIA and LPS-induced inflammatory arthritis model.

[1]  E. Riley,et al.  Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease , 2013, Front. Immunol..

[2]  D. Yoon,et al.  Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals , 2013, Cell Death and Disease.

[3]  L. Joosten,et al.  Novel insights into the biology of interleukin-32 , 2013, Cellular and Molecular Life Sciences.

[4]  Mingli Xiang,et al.  SKLB023 Blocks Joint Inflammation and Cartilage Destruction in Arthritis Models via Suppression of Nuclear Factor-Kappa B Activation in Macrophage , 2013, PloS one.

[5]  C. Akdis,et al.  Inhibition of angiogenesis by IL-32: possible role in asthma. , 2012, The Journal of allergy and clinical immunology.

[6]  J. Zachary,et al.  Localized Production of IL-10 Suppresses Early Inflammatory Cell Infiltration and Subsequent Development of IFN-γ–Mediated Lyme Arthritis , 2012, The Journal of Immunology.

[7]  H. J. Kim,et al.  IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals , 2011, Oncogene.

[8]  L. Joosten,et al.  Inflammation-dependent secretion and splicing of IL-32γ in rheumatoid arthritis , 2011, Proceedings of the National Academy of Sciences.

[9]  L. Joosten,et al.  Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade , 2010, Annals of the rheumatic diseases.

[10]  C. Dinarello,et al.  Paradoxical effects of constitutive human IL-32γ in transgenic mice during experimental colitis , 2010, Proceedings of the National Academy of Sciences.

[11]  Hua Huang,et al.  IL-32 Is a Host Protective Cytokine against Mycobacterium tuberculosis in Differentiated THP-1 Human Macrophages , 2010, The Journal of Immunology.

[12]  Y. Shyr,et al.  Interleukin-32β Propagates Vascular Inflammation and Exacerbates Sepsis in a Mouse Model , 2010, PloS one.

[13]  D. Yoon,et al.  A proinflammatory cytokine interleukin‐32β promotes the production of an anti‐inflammatory cytokine interleukin‐10 , 2009, Immunology.

[14]  D. Yoon,et al.  Identification of the most active interleukin‐32 isoform , 2009, Immunology.

[15]  G. Mabilleau,et al.  Interleukin-32 Promotes Osteoclast Differentiation but Not Osteoclast Activation , 2009, PloS one.

[16]  P. Allavena,et al.  Cancer related inflammation: the macrophage connection. , 2008, Cancer letters.

[17]  D. Yoon,et al.  Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. , 2008, Journal of immunological methods.

[18]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[19]  Y. Kochi,et al.  Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases , 2006, Arthritis research & therapy.

[20]  C. Dinarello,et al.  IL-32, a novel cytokine with a possible role in disease , 2006, Annals of the rheumatic diseases.

[21]  L. Joosten,et al.  Mycobacterium tuberculosis Induces Interleukin-32 Production through a Caspase- 1/IL-18/Interferon-γ-Dependent Mechanism , 2006, PLoS medicine.

[22]  Do-Young Yoon,et al.  IL-32, a proinflammatory cytokine in rheumatoid arthritis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Ohno,et al.  Involvement of IL-32 in activation-induced cell death in T cells. , 2006, International immunology.

[24]  P. Tak,et al.  Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA , 2001, Annals of the rheumatic diseases.

[25]  G. Burmester,et al.  [The immunologic homunculus in rheumatoid arthritis. A new viewpoint of immunopathogenesis in rheumatoid arthritis and therapeutic consequences]. , 2001, Zeitschrift fur Rheumatologie.

[26]  O. Meyer.  [Role of anti-TNF therapy in rheumatoid arthritis]. , 2000, Presse medicale.

[27]  Huiling He,et al.  Identification of a novel gene expressed in activated natural killer cells and T cells. , 1992, Journal of immunology.

[28]  I. Hunneyball,et al.  Antigen-induced arthritis in mice. , 1986, British journal of clinical practice. Supplement.

[29]  M. Ehrenstein,et al.  Cells of the synovium in rheumatoid arthritis B cells , 2007 .

[30]  A. Takayanagi,et al.  Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. , 2007, Clinical and experimental immunology.

[31]  D. Yoon,et al.  Interleukin-32: a cytokine and inducer of TNFalpha. , 2005, Immunity.

[32]  M. Mayo,et al.  Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. , 1999, The Journal of biological chemistry.